Drugs / Lym-1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00009776 | Mar 2001 → ? | lymphoma | University of California, Davis | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00008021 Background | Feb 2001 → ? | lymphoma | University of California, Davis | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lym-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00009776 ↗ |
| Known as | MOAB Lym-1 | “Patients receive unlabeled monoclonal antibody (MOAB) Lym-1 IV followed by a tracer dose of indium In 111 MOAB Lym-1 (In111 MOAB Lym-1) IV on day 0 and unlabeled MOAB Lym-1 IV...” NCT00008021 ↗1“Patients receive unlabeled MOAB Lym-1 IV followed by a tracer dose of indium In 111 MOAB Lym-1 IV on day 0.” NCT00009776 ↗ |
| Known as | Oncolym | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109447 ↗ |
| Modality | Monoclonal antibody | “Patients receive unlabeled monoclonal antibody (MOAB) Lym-1 IV followed by a tracer dose of indium In 111 MOAB Lym-1 (In111 MOAB Lym-1) IV on day 0 and unlabeled MOAB Lym-1 IV...” NCT00008021 ↗ |
| Route | Intravenous | “unlabeled monoclonal antibody (MOAB) Lym-1 IV” NCT00008021 ↗ |
| Target | HLA-DRB1 | “HLA class II histocompatibility antigen, DRB1-15 beta chain other” CHEMBL2109447 ↗ |